Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinal Stem and Progenitor Cells for AMD
NCT05187104Phase 2Unknown
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of autologous retinal stem and progenitor cells in age-related macular degeneration (AMD) (2 arms). Primary endpoints: Visual acuity at 1 month and Adverse effects associated with the therapy at 1 month. Status: unknown.
02
Drugs
autologous retinal stem and progenitor cells
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT05187104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187104.